Substance / Medication

Mebendazole

Overview

Active Ingredient
mebendazole
RxNorm CUI
6672

Indications

Ascaris lumbricoides Trichuris trichiura VERMOX™ CHEWABLE is indicated for the treatment of patients one year of age and older with gastrointestinal infections caused by(roundworm) and(whipworm).

Labeler: Janssen Pharmaceuticals, Inc.Updated: 2021-10-05T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

VERMOX™ CHEWABLE is contraindicated in persons with a known hypersensitivity to the drug or its excipients.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

8 trials linked to this intervention

8
Total Trials
3
Recruiting
0
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Efficacy of mebendazole in paediatric patients with giardiasis: A systematic review and meta-analysis.
Escobedo Angel A, Almirall Pedro, González-Fraile Eduardo et al. · Acta Trop · 2018
PMID: 30092225Meta-Analysis
Mebendazole; from an anti-parasitic drug to a promising candidate for drug repurposing in colorectal cancer.
Hegazy Sahar K, El-Azab Gamal A, Zakaria Fatma et al. · Life Sci · 2022
PMID: 35385794RCT
Adverse Events from a Randomized, Multi-Arm, Placebo-Controlled Trial of Mebendazole in Children 12-24 Months of Age.
Joseph Serene A, Montresor Antonio, Casapía Martín et al. · Am J Trop Med Hyg · 2016
PMID: 27139441RCTFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Mebendazole (substance)
SNOMED CT
387311004
UMLS CUI
C0025023
RxNorm CUI
6672
Labeler
Janssen Pharmaceuticals, Inc.

Clinical Data

This intervention maps to 5 entities in the Ltrl knowledge graph.

5
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
8
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.